BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 10658445)

  • 1. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
    Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
    Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
    Belcaro G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
    Bucci M; Iacobitti P; Laurora G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
    De Sanctis MT; Incandela L; Iacobitti P
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
    Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Circadian variations of cutaneous blood flow in normal subjects and in patients with peripheral arteriopathies. Effect of PGE1 and alpha-cyclodextrin].
    Laurora G; Belcaro G
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):45-9. PubMed ID: 10658444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
    Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
    Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intramuscular injections of PGE1 in patients with severe claudication].
    Corsi M; Laurora G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
    Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
    Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
    Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
    Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glomerular morphologic protection after acute ischemia through the administration of Surgiran: (PGE1 and Alfadex, glucose cyclic oligomer). Morphometric study].
    Conde Redondo C; Herreros Rodríguez V; Rodríguez-Toves LA; Estabanez Zarranz J; Martínez Sagarra JM; Vaquero C
    Arch Esp Urol; 2002 Apr; 55(3):241-50. PubMed ID: 12068755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.
    Belcaro G; Nicolaides AN; Cipollone G; Laurora G; Incandela L; Cazaubon M; Barsotti A; Ledda A; Errichi BM; Cornelli U; Dugall M; Corsi M; Mezzanotte L; Geroulakos G; Fisher C; Szendro G; Simeone E; Cesarone MR; Bucci M; Agus G; De Sanctis MT; Ricci A; Ippolito E; Vasdekis S; Christopoulos D; Helmis H
    Angiology; 2000 Aug; 51(8 Pt 2):S3-13; discussion S14. PubMed ID: 10959506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K; Tanaka M; Misawa H; Takigawa T; Ozaki T
    Spine (Phila Pa 1976); 2008 Jun; 33(13):1465-9. PubMed ID: 18520942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term (four years) follow-up of patients with treated nocturnal hypertension assessed by ambulatory blood pressure monitoring.
    Carmona J; Amado P; Vasconcelos N; Santos I; Almeida L; Teles J; Nazaré J
    Rev Port Cardiol; 2001 Feb; 20(2):135-50; discussion 153-4. PubMed ID: 11293873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Did the arrival of prostanoids modify therapeutic indications in peripheral obstructive arteriopathies? Considerations based on our experience].
    Cardia G; Tumolo R; Cuscito C
    G Chir; 1997 May; 18(5):297-300. PubMed ID: 9312259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Short- and long-term evaluation of treatment of critical ischemia of the lower lim with PGE1 (alprostadyl alpha-cyclodestrine)].
    Amitrano M; Izzo M; Castaldo G; Lombardi R; Tizzano R; Bellizzi AM; Vietri GC; Sorrentino A; D'Avanzo A
    Minerva Cardioangiol; 1996; 44(7-8):391-6. PubMed ID: 8965998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two randomised and placebo-controlled studies of an oral prostacyclin analogue (Iloprost) in severe leg ischaemia. The Oral Iloprost in severe Leg Ischaemia Study Group.
    Eur J Vasc Endovasc Surg; 2000 Oct; 20(4):358-62. PubMed ID: 11038148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.